relugolix
takeda,gedeon richter,aska pharmaceuticals,intas,sumitomo dainippon
['hero', 'relugolix']
subgroup analysis from hero: efficacy and safety of relugolix based on baseline bmi castration rates: for the relugolix v leuprolide across all bmi subgroups psa response proportions: lower in obese men no differences in aes #asco22 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday